Tezspire recommended for EU approval in asthma
25 July 2022 07:10 BST Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations AstraZeneca's Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products